Idera Pharmaceuticals
Idera Pharmaceuticals is a company.
Active
Updated: ·
Financial History
Total Raised
N/A
Valuation
N/A
Leadership Team
Key people at Idera Pharmaceuticals.
Idera Pharmaceuticals is a company.
Key people at Idera Pharmaceuticals.
Key people at Idera Pharmaceuticals.
Idera Pharmaceuticals was a clinical-stage biopharmaceutical company focused on discovering, developing, and commercializing nucleic acid therapeutics, primarily using Toll-like receptor (TLR) targeting technology for rare diseases and oncology.[1][2] Its lead candidates included tilsotolimod for anti-PD-1 refractory metastatic melanoma and other cancers, addressing unmet needs in immuno-oncology with improved patient response rates and low added toxicity.[1][5] The company served patients with rare diseases and hard-to-treat cancers, solving problems like limited treatment options in refractory melanoma through intratumoral TLR-9 agonists combined with therapies like ipilimumab.[1][5] Founded in 1989, it raised $395.1 million in funding, employed 22 people, and generated $662,000 in revenue before its acquisition by Aceragen, Inc. in July 2021 (merger completed September 2022, name change to Aceragen in early 2023).[1][2][3]
Idera Pharmaceuticals was founded in 1989 as a biotechnology research firm initially centered on nucleic acid-based drug discovery.[2] It evolved from broad drug development into a specialist in TLR-targeting platforms, with key programs like tilsotolimod emerging as pivotal assets in immuno-oncology.[1][5] Headquartered in Exton, Pennsylvania (with R&D in Cambridge, MA, and later ties to Durham, NC), the company built early traction through global clinical trials and partnerships, achieving rapid Phase 3 enrollment (294 of 300 patients by August 2019) via strong data from Phase 2 studies and collaboration with CRO Medpace.[1][5] Leadership under CEO Vin Milano emphasized patient recruitment success and scientific rigor, leading to the 2021 acquisition by Aceragen, which integrated Idera's oncology assets into rare disease-focused programs like ACG-701 for cystic fibrosis exacerbations and ACG-801 for Farber disease.[1][3]
Idera rode the immuno-oncology wave, particularly TLR agonists combined with checkpoint inhibitors, capitalizing on the post-2010s surge in precision biologics for refractory cancers amid growing rare disease investment.[1][5] Timing aligned with regulatory support for orphan indications and accelerated approvals, as seen in Aceragen's inherited Fast Track/Orphan Drug statuses, amid market forces like rising cystic fibrosis prevalence and ultra-rare disease incentives (e.g., priority review vouchers).[3] By proving scalable recruitment in challenging trials, Idera influenced biopharma ecosystems, highlighting efficient CRO models and data-centric strategies that reduced delays in a sector where 80%+ of trials face enrollment hurdles.[5] Post-acquisition, its assets bolstered Aceragen's portfolio, contributing to rare disease momentum in biotech M&A.
Idera's legacy endures through Aceragen (formerly IDRA), with near-term catalysts like Phase 2 readouts for ACG-701 in cystic fibrosis (2024) and Phase 2/3 initiation for ACG-801 in Farber disease (Q1 2024, data Q1 2025), potentially enabling registration in ultra-rare settings.[3] Evolving trends in gene/immune therapies and rare disease vouchers will shape Aceragen's path, amplifying Idera's TLR tech in combo regimens. Its influence may grow via successful integration, delivering first-in-class options for unmet needs and validating acquisition-driven biotech consolidation.[1][3] This positions Aceragen—and Idera's foundational innovations—as key players in transforming rare disease care.
